Servier Singled Out for New EU Antitrust Investigation

Jul 08, 2009
By Pharmaceutical Executive

As well as the reprimands and warnings from the European Commission's much anticipated report on its Big Pharma antitrust investigations on Wednesday was the announcement that the EC is launching a new investigation into Servier. The regulators are accusing the private-held French company of hindering the launch of generic versions of its heart disease drug, perindopril, saying they suspect that the company did deals with generic rivals Krka, Lupin, Matrix, Niche Generics Ltd and Teva to hold back cheaper versions.